Neurology Central

FENS 2018: CRISPR–Cas gene editing could treat Huntington’s disease

Neuroscientists from Lausanne University Hospital (Lausanne, Switzerland) have found a way to disrupt the damaging effects of the mutated gene responsible for Huntington’s disease (HD).

The research, presented at the 11th FENS Forum of Neuroscience (7–11 July, Berlin, Germany), highlights the therapeutic potential of the CRISPR–Cas gene editing technology to manipulate DNA in the brains of mouse models.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.